This study also used 111In-PSMA-NARI-56/nanoSPECT/CT imaging, as shown in Figure 3, to evaluate the tumor dimensions in mice treated with 177Lu-PSMA-NARI-56 at specific time points (−day 2 (two days prior to experiment), day 25, day 39, and day 60). Here, FOLH1 is linked to neoplasm.